Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia - Background and results

Inflammation Research

Volumn 58, Issue SUPPL. 1, 2009, Pages

  Brune, M ^a   Romero, A I ^a   Hellstrand, K ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG POTENTIATION; FATIGUE; FEVER; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; INJECTION SITE INFLAMMATION; KIDNEY CARCINOMA; LEUKEMIA REMISSION; MELANOMA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MYALGIA; NATURAL KILLER CELL; OVERALL SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE;

CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; HISTAMINE; HISTAMINE AGONISTS; HUMANS; INTERLEUKIN-2; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION;

EID: 63949085954     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-009-0642-1     Document Type: Article

References (16)

1. Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003; 21:4496-504.
2. Brune M., Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol 1996; 92:620-6.
3. Blaise D, Attal M, Reiffers J, Michallet M, Bellanger C, Pico JL, et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000; 11:91-8.
4. BaerMR, George SL, CaligiuriMA, Sanford BL, O'Loughlin KL, Mrozek K, et al. Phase III study of immunotherapy with recombinant interleukin-2 (IL-2) versus no further therapy in acute myeloid leukemia (AML) patients ≥ 60 years in first complete remission (CALGB 9720). Am Soc Hematol 2006; Abstract 424.
5. Kolitz JE, Hars V, DeAngelo DJ, Allen SL, Shea TC, Vij R, et al. Phase III Trial of Immunotherapy with Recombinant Interleukin2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808. Am. Soc Hematol 2007; Abstract 157.
6. Pautas C, Thomas X, Merabet F, Raffoux E, Bourhis JH, De Botton S, et al. Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study. Am Soc Hematol. 2007; Abstract 162.
7. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial, for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008; 111:1044-53.
8. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia : results of a randomized phase 3 trial. Blood 2006; 108:88-96.
9. Romero AI, Thoren FB, Brune M, Hellstrand K, Histamine Dihydrochloride Maintains Cytotoxic Effector T Lymphocyte Function and Viability under Conditions of Oxidative Stress. Am Soc Hematol 2007; Abstract 2309.
10. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996; 156:42-7.
11. Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, Hellstrand K. Natural, killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood 2000; 96:1961-8.
12. Thoren FB, Romero AI, Hellstrand K. Oxygen radicals induce poly(ADP-ribose) polymerase-dependent cell death in cytotoxic lymphocytes. J Immunol 2006; 176:7301-7.
13. Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol 1994; 153:4940-7.
14. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 345:1144-6.
15. Donskov F, Hokland M, Marcussen N, Torp Madsen HH, von der Maase H. Monocytes and neutrophils as 'bad guys' for the out-come of interleukin-2 with and without histamine in metastatic renal cell carcinoma - results from a randomised phase II trial. Br J Cancer 2006; 94:218-26.
16. Brune M, Hansson M, Mellqvist UH, Hermodsson S, Hellstrand K. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1.996; 57:312-9.